AnaptysBio, Inc. (NASDAQ:ANAB) Director Purchases $86,065.70 in Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc acquired 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The shares were purchased at an average price of $12.95 per share, with a total value of $86,065.70. Following the completion of the purchase, the director now owns 7,880,094 shares in the company, valued at $102,047,217.30. This represents a 0.08 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc purchased 65,184 shares of AnaptysBio stock. The shares were purchased at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Stock Performance

NASDAQ ANAB opened at $14.60 on Friday. The business’s fifty day moving average is $19.75 and its 200 day moving average is $28.43. AnaptysBio, Inc. has a fifty-two week low of $12.51 and a fifty-two week high of $41.31. The company has a market capitalization of $444.26 million, a PE ratio of -2.40 and a beta of -0.11.

AnaptysBio (NASDAQ:ANAB) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its stake in AnaptysBio by 1.8% in the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company’s stock worth $745,000 after buying an additional 525 shares in the last quarter. Algert Global LLC grew its position in shares of AnaptysBio by 11.8% during the second quarter. Algert Global LLC now owns 10,178 shares of the biotechnology company’s stock worth $255,000 after purchasing an additional 1,078 shares in the last quarter. nVerses Capital LLC raised its stake in AnaptysBio by 700.0% during the 3rd quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 1,400 shares during the period. Values First Advisors Inc. purchased a new position in AnaptysBio in the 3rd quarter worth approximately $49,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in AnaptysBio by 81.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,808 shares of the biotechnology company’s stock worth $195,000 after purchasing an additional 2,600 shares during the period.

Analyst Ratings Changes

Several research analysts have recently weighed in on ANAB shares. Wedbush restated an “outperform” rating and issued a $40.00 price target (down previously from $42.00) on shares of AnaptysBio in a research note on Wednesday, December 11th. JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. Wells Fargo & Company decreased their price objective on shares of AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Guggenheim dropped their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. Finally, Truist Financial decreased their target price on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $41.45.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.